Scientists in Germany have discovered why the medication thalidomide appeared safe in animal tests before going on the market 50 years ago, only to cause perhaps the most extensive outbreak of drug-induced birth defects in medical history. Their study is scheduled for the December 1 edition of ACS' Molecular Pharmaceutics.
Jurgen Knobloch, Ulrich Ruther and colleagues note that more than 10,000 children were born with severe birth defects after drug regulators in Europe approved the medication for treating nausea and vomiting in pregnant women. The drug, never approved for that use in the United States, is available for certain conditions, including multiple myeloma and leprosy. The birth defects outbreak puzzled scientists because pre-marketing tests in lab mice and rats showed no sign of a birth defect risk.
The researchers point out that those animals proved to be resistant to thalidomide's adverse effects, and in the new study they describe discovery of the biochemical basis for that resistance. It involves a key difference between human embryonic cells and those of mice. They found in mice cells advanced antioxidant defenses compared to those in humans and other thalidomide-susceptible species.
Therefore, thalidomide is not able to induce the generation of large quantities of damaging free radicals called superoxides in mouse embryonic cells as it does in human embryonic cells (where subsequent cell death is believed to be responsible for birth defects.)
Article: "Thalidomide Resistance Is Based on the Capacity of the Glutathione-Dependent Antioxidant Defense",
http://dx.doi.org/10.1021/mp8001232
Source: ACS
Related stories:
Scientists succeed through stem cell therapy in reversing brain birth defects
Scientists at the Hebrew University of Jerusalem have succeeded in reversing brain birth defects in animal models, using stem cells to replace defective brain cells.
Newly found enzymes may play early role in cancer
Researchers have discovered two enzymes that, when combined, could be involved in the earliest stages of cancer. Manipulating these enzymes genetically might lead to targeted therapies aimed at slowing or preventing the onset of tumors.
EPA veils hazardous substances
The U.S. Environmental Protection Agency routinely allows companies to keep new information about their chemicals secret, including compounds that have been shown to cause cancer and respiratory problems, the Milwaukee Journal Sentinel has found.
Microarray analysis improves prenatal diagnosis
A "chip" or array that can quickly detect disorders such as Down syndrome or other diseases associated with chromosomal abnormalities proved an effective tool in prenatal diagnosis in a series of 300 cases at Baylor College of Medicine, said researchers in a report that appears in the current issue of the journal
Prenatal Diagnosis.
New study bolsters beliefs about DNA repair
Aucott et al. report the first in vivo experiments on the heterochromatin protein 1 (HP1) family, which sidles up to silent DNA. The results, to be published in the Nov. 17 issue of the
Journal of Cell Biology, add to the evidence that the different versions of the proteins help cells fix broken DNA.
Chicks to give scientists clearer picture of fetal development
Scientists hope to gain a greater understanding of disease and birth defects with a new imaging database that will map the expression of genes that control development.
Researchers uncover genetic basis for some birth defects
A multidisciplinary research team at Case Western Reserve University led by Gary Landreth, Ph.D., a professor in the School of Medicine's Department of Neurosciences, has uncovered a common genetic pathway for a number of birth defects that affect the development of the heart and head. Abnormal development of the jaw, palate, brain and heart are relatively common congenital defects and frequently arise due to genetic errors that affect a key developmental pathway.
Umbilical cord blood may help build new heart valves
Children with heart defects may someday receive perfectly-matched new heart valves built using stem cells from their umbilical cord blood, according to research presented at the American Heart Association's Scientific Sessions 2008.